Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | FDFT1 | P37268 | 2/20 | 0.40 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3740691 | 0.84 | KCNH2 (0.56) | UTS2RTAAR1KCNH2TMEM97MAOB | |
| SCHEMBL8242110 | 0.84 | TACR1 (0.47) | TAAR1KCNH2MAOBCCR3 | |
| SCHEMBL3738246 | 0.84 | TACR1 (0.50) | TAAR1KCNH2TMEM97MAOBFDFT1 | |
| SCHEMBL3604156 | 0.84 | TACR1 (0.47) | TAAR1KCNH2MAOBCCR3 | |
| SCHEMBL3732187 | 0.84 | MEN1 (0.60) | TAAR1MAOBMEN1KMT2ACCR3 | |
| SCHEMBL3730922 | 0.84 | MEN1 (0.60) | TAAR1MAOBMEN1KMT2ACCR3 | |
| Hydrochloric Acid SCHEMBL3733660 | 0.83 | KCNH2 (0.55) | UTS2RTAAR1KCNH2TMEM97MAOB | |
| Hydrochloric Acid SCHEMBL2321850 | 0.83 | TACR1 (0.46) | TAAR1KCNH2MAOBCCR3 | |
| Hydrochloric Acid SCHEMBL3746416 | 0.83 | TACR1 (0.49) | TAAR1KCNH2MAOBMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL2321848 | 0.83 | TACR1 (0.46) | TAAR1KCNH2MAOBCCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114867-B1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-12-12 | — | — | EP | disclosed |
| US-7829563-B2 | Aminoamides as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20080221166-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221166-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HCRTR1, HCRTR2, HRH3 | UTS2R 221/4885TAAR1 34/4885BCHE 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.